Stock Events

Stock Events

Amylyx Pharmaceuticals 

$14.35
94
+$0.45+3.24% Today

Statistics

Day High
14.66
Day Low
13.88
52W High
17.49
52W Low
3.11
Volume
816,962
Avg. Volume
1,281,096
Mkt Cap
1.58B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 18
$0.42
Jan 18
$0.36
Oct 17
$0.24
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.07
-0.81
-0.56
-0.3
Expected EPS
-0.326294
Actual EPS
N/A

Financials

-345.36%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
174.74MRevenue
-603.49MNet Income

Analyst Ratings

$23.83Average Price Target
The highest estimate is 34.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMLX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a biopharmaceutical company that competes with Amylyx in the neurodegenerative diseases market, particularly in treatments for ALS and Alzheimer's disease.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, competing in the same space as Amylyx by targeting neurological disorders including ALS.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics, directly competing with Amylyx in developing treatments for rare neurological diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that has a broad portfolio, including treatments for neurological conditions like ALS, making it a competitor to Amylyx.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG competes with Amylyx in the neurology space, particularly in developing treatments for spinal muscular atrophy and other neurodegenerative diseases.
PTC
PTC
Mkt Cap23.78B
PTC Therapeutics operates in the field of genetic disorders, including ALS and other neurological conditions, making it a competitor to Amylyx.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. focuses on developing therapies for Alzheimer's and other central nervous system diseases, competing with Amylyx in the neurodegenerative space.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare genetic diseases with some overlap in the neurological space, making it a competitor to Amylyx.
Akebia Therapeutics
AKBA
Mkt Cap585.97M
Akebia Therapeutics, while primarily focused on kidney disease, is exploring treatments in related areas that could compete with Amylyx's neurological disease focus.

About

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Joshua B. Cohen
Employees
123
Country
US
ISIN
US03237H1014

Listings

XNAS
US
AMLX
BOATS
BOATS
AMLX.BOATS

0 Comments

Share your thoughts

FAQ

What is Amylyx Pharmaceuticals stock price today?▼
The current price of AMLX is $14.35 USD — it has increased by +3.24% in the past 24 hours. Watch Amylyx Pharmaceuticals stock price performance more closely on the chart.
What is Amylyx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amylyx Pharmaceuticals stocks are traded under the ticker AMLX.
Is Amylyx Pharmaceuticals stock price growing?▼
AMLX stock has risen by +3.76% compared to the previous week, the month change is a -5.41% fall, over the last year Amylyx Pharmaceuticals has showed a +329.64% increase.
What is Amylyx Pharmaceuticals market cap?▼
Today Amylyx Pharmaceuticals has the market capitalization of 1.58B
When is the next Amylyx Pharmaceuticals earnings date?▼
Amylyx Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Amylyx Pharmaceuticals earnings last quarter?▼
AMLX earnings for the last quarter are -0.3 USD per share, whereas the estimation was -0.35 USD resulting in a +14.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amylyx Pharmaceuticals revenue for the last year?▼
Amylyx Pharmaceuticals revenue for the last year amounts to 174.74M USD.
What is Amylyx Pharmaceuticals net income for the last year?▼
AMLX net income for the last year is -603.49M USD.
Does Amylyx Pharmaceuticals pay dividends?▼
Yes, AMLX dividends are paid quarterly. The last dividend per share was 0.42 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Amylyx Pharmaceuticals have?▼
As of April 01, 2026, the company has 123 employees.
In which sector is Amylyx Pharmaceuticals located?▼
Amylyx Pharmaceuticals operates in the Health Care sector.
When did Amylyx Pharmaceuticals complete a stock split?▼
Amylyx Pharmaceuticals has not had any recent stock splits.
Where is Amylyx Pharmaceuticals headquartered?▼
Amylyx Pharmaceuticals is headquartered in Cambridge, US.